Multiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy

BACKGROUND: Immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized cancer therapy. However, therapeutic targeting of inhibitory T cell receptors such as PD-1 not only initiates a broad immune response against tumors, but also causes severe adverse effects. An ideal future stratifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Heumos, Simon, Dehn, Sandra, Bräutigam, Konstantin, Codrea, Marius C., Schürch, Christian M., Lauer, Ulrich M., Nahnsen, Sven, Schindler, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555072/
https://www.ncbi.nlm.nih.gov/pubmed/36221114
http://dx.doi.org/10.1186/s12935-022-02710-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555072/
https://www.ncbi.nlm.nih.gov/pubmed/36221114
http://dx.doi.org/10.1186/s12935-022-02710-y

Ejemplares similares